Molecular diagnostics firm XDx has appointed Matthew Meyer as vice president of corporate development and legal affairs, the company said this week.
Prior to joining XDx, Meyer was vice president of business development and general counsel at Cerimon Pharmaceuticals. Prior to that, he held various senior management positions, most recently vice president and general counsel, at Draeger Medical Systems. He has also worked for Novartis, Allscripts, and Pfizer. Meyer holds a JD from Villanova University Law School and a BA from Cornell University.
QuantRx Biomedical said this week that Walter Witoshkin has stepped down from his posts as chairman and CEO as part of the consolidation and relocation of the company's operations to Portland, Ore. Meantime, Barry London has been appointed interim CEO and a member of QuantRx's board; and Shalom Hirschman has been appointed chairman.
London has more than 30 years of business and legal experience at several companies in the finance and healthcare industries. He holds degrees from the Wharton School of Finance and Commerce and the University of Pennsylvania School of Law.
Hirschman has served as a member of QuantRx's board since September 2005. Prior to that, he served on the board of QuantRx predecessor A-Fem Medical. Hirschman was a professor of medicine, director of the infectious diseases division, and vice chairman of the department of medicine at Mt. Sinai School of Medicine and Mount Sinai Hospital. He has also served as CSO of Advanced Viral Research, from which he retired in 2004.